Pharma Mar, S.A.
PHMMFOTCHealthcare● Active
$106.48
+$0.00(+0.00%)
Market Cap$1.8B
P/E Ratio—
52W High$110.4
52W Low$80.91
Pharma Mar, S.A. (PHMMF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PHMMF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
$0.10
Est. $0.14 · -32.0%
Revenue
$0.05B
Est. $0.05B · -0.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▼ Miss EPS
PHMMF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $0.21 | — | — | — | $0.05B | — |
| ▼ Q2 FY2026 | Apr 29, 2026 | $0.14 | $0.10 | -32.0% | $0.05B | $0.05B | -0.9% |
| ▲ Q1 FY2026 | Feb 27, 2026 | $3.61 | $3.92 | +8.6% | $0.11B | $0.10B | +2.7% |
| ▲ Q3 FY2025 | Jul 30, 2025 | $0.04 | $1.59 | +4399.1% | $0.07B | $0.03B | +90.8% |
| ▼ Q2 FY2025 | Apr 21, 2025 | $0.34 | -$0.25 | -173.4% | $0.04B | $0.04B | +8.1% |
| ▲ Q1 FY2025 | Feb 26, 2025 | $1.00 | $1.10 | +10.0% | $0.05B | $0.04B | +23.6% |
| ▲ Q4 FY2024 | Oct 29, 2024 | $0.23 | $0.24 | +6.3% | $0.05B | $0.05B | -1.8% |
| ▲ Q3 FY2024 | Jul 30, 2024 | $0.01 | $0.08 | +604.0% | $0.05B | $0.05B | +0.8% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$0.21
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026Miss
EPS Actual
$0.10
EPS Est.
$0.14
EPS Surpr.
-32.0%
Revenue
$0.05B
Q1 FY2026
Feb 27, 2026Beat
EPS Actual
$3.92
EPS Est.
$3.61
EPS Surpr.
+8.6%
Revenue
$0.11B
Q3 FY2025
Jul 30, 2025Beat
EPS Actual
$1.59
EPS Est.
$0.04
EPS Surpr.
+4399.1%
Revenue
$0.07B
Q2 FY2025
Apr 21, 2025Miss
EPS Actual
-$0.25
EPS Est.
$0.34
EPS Surpr.
-173.4%
Revenue
$0.04B
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
$1.10
EPS Est.
$1.00
EPS Surpr.
+10.0%
Revenue
$0.05B
Q4 FY2024
Oct 29, 2024Beat
EPS Actual
$0.24
EPS Est.
$0.23
EPS Surpr.
+6.3%
Revenue
$0.05B
Q3 FY2024
Jul 30, 2024Beat
EPS Actual
$0.08
EPS Est.
$0.01
EPS Surpr.
+604.0%
Revenue
$0.05B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $1.45 | $1.67 | $1.89 | 1 |
| Q3 FY2026 | $0.18 | $0.20 | $0.23 | 1 |
| Q2 FY2026 | $0.16 | $0.18 | $0.21 | 1 |
| Q1 FY2026 | $0.11 | $0.13 | $0.14 | 1 |
| Q4 FY2025 | $2.67 | $3.07 | $3.48 | 1 |
| Q3 FY2025 | $-0.16 | $-0.16 | $-0.15 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.1B | 3 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
| Q4 FY2025 | $0.1B | $0.1B | $0.1B | 5 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 29, 2026 | -32.0% | $106.48 | $106.48 | +0.00% |
| ▲ Q1 FY2026 | Feb 27, 2026 | +8.6% | $88.72 | $88.72 | +0.00% |
| ▲ Q3 FY2025 | Jul 30, 2025 | +4399.1% | $91.22 | $91.22 | +0.00% |
| ▼ Q2 FY2025 | Apr 21, 2025 | -173.4% | $88.18 | $88.18 | +0.00% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +10.0% | $95.79 | $95.79 | +0.00% |
| ▲ Q4 FY2024 | Oct 29, 2024 | +6.3% | $75.00 | $75.00 | +0.00% |
| ▲ Q3 FY2024 | Jul 30, 2024 | +604.0% | $34.26 | $34.26 | +0.00% |
| ▲ Q2 FY2024 | Apr 23, 2024 | +286.8% | $26.85 | $26.85 | +0.00% |
Q2 FY2026+0.00%
Report Date
Apr 29, 2026
EPS Beat/Miss
-32.0%
Price Before
$106.48
Price After
$106.48
Q1 FY2026+0.00%
Report Date
Feb 27, 2026
EPS Beat/Miss
+8.6%
Price Before
$88.72
Price After
$88.72
Q3 FY2025+0.00%
Report Date
Jul 30, 2025
EPS Beat/Miss
+4399.1%
Price Before
$91.22
Price After
$91.22
Q2 FY2025+0.00%
Report Date
Apr 21, 2025
EPS Beat/Miss
-173.4%
Price Before
$88.18
Price After
$88.18
Q1 FY2025+0.00%
Report Date
Feb 26, 2025
EPS Beat/Miss
+10.0%
Price Before
$95.79
Price After
$95.79
Q4 FY2024+0.00%
Report Date
Oct 29, 2024
EPS Beat/Miss
+6.3%
Price Before
$75.00
Price After
$75.00
Q3 FY2024+0.00%
Report Date
Jul 30, 2024
EPS Beat/Miss
+604.0%
Price Before
$34.26
Price After
$34.26
Q2 FY2024+0.00%
Report Date
Apr 23, 2024
EPS Beat/Miss
+286.8%
Price Before
$26.85
Price After
$26.85
Avg Beat Reaction+0.00%
Avg Miss Reaction+0.00%
Beat Rate6 / 8 quarters
Largest Move+0.00% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PHMMF ends December
Pharma Mar, S.A. (PHMMF) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $0.10 — missing the analyst consensus of $0.14 by -32.0%. The next PHMMF earnings date is expected around September 1, 2026.
Each quarter, investors track PHMMF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PHMMF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PHMMF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PHMMF earnings · 5 questionsPharma Mar, S.A.'s next earnings report is expected around September 1, 2026. PHMMF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PHMMF historically reports after market close (AMC).
PHMMF earnings datewhen is PHMMF earningsPHMMF next earnings datewhen does PHMMF report earningsPHMMF earnings calendar
▸ Source: FMP · Pharma Mar, S.A. SEC filings · US GAAP · Pharma Mar, S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026